12485Anhui Medical University, Hefei, China.
Yang Yang and Fanfan Li are Co-corresponding author in the manuscript.
Int J Biol Markers. 2022 Sep;37(3):260-269. doi: 10.1177/03936155221110249. Epub 2022 Jul 6.
) participates in tumor resistance by playing the function of homologous recombination repair(HRR). However, the role of in non-small cell lung cancer (NSCLC) is still unclear. This study aims to understand the expression of in NSCLC and preliminarily explore its relationship with cisplatin resistance.
messenger RNA (mRNA) was analyzed in 1018 NSCLC tissues and 111 adjacent tissues using The Cancer Genome Atlas program. mRNA in cisplatin-resistant and cisplatin-sensitive cell lines was analyzed by the Gene Expression Omnibus project. FIGNL1 protein was detected in 58 NSCLC tissues and 58 adjacent tissues by immunohistochemistry. The relationship between FIGNL1, clinical pathological characteristics and disease-free survival was retrospectively analyzed. Gene ontology was used to analyze the biological process mainly involving , and STRING online constructed its protein interaction network and screened the key genes (hub genes).
The Cancer Genome Atlas showed that mRNA was higher in 1018 NSCLC tissues than in 111 adjacent tissues ( < 0.05). In the dataset "GSE157692," mRNA was higher in cisplatin-resistant cell lines ( = 3.80e-05). The hub genes in and HRR directions are and . Immunohistochemistry showed that the FIGNL1 protein in 58 NSCLC tissues was higher than that in 58 adjacent tissues ( < 0.01). FIGNL1 is associated with gender, histopathological type, and nerve invasion in NSCLC. The disease-free survival in NSCLC patients with high FIGNL1 expression was shorter ( = 0.032).
FIGNL1 is associated with poor prognosis in NSCLC, and cisplatin resistance may be involved. These observations provide a clinical basis for exploring FIGNL1 as a potential biomarker for cisplatin resistance in NSCLC.
在发挥同源重组修复（HRR）功能方面， 参与肿瘤耐药。然而， 在非小细胞肺癌（NSCLC）中的作用尚不清楚。本研究旨在了解 NSCLC 中 的表达，并初步探讨其与顺铂耐药的关系。
利用癌症基因组图谱（TCGA）计划分析了 1018 例 NSCLC 组织和 111 例相邻组织中的信使 RNA（mRNA）。通过基因表达综合数据库（GEO）项目分析了顺铂耐药和敏感细胞系中的 mRNA。采用免疫组织化学法检测 58 例 NSCLC 组织和 58 例相邻组织中的 FIGNL1 蛋白。回顾性分析 FIGNL1 与临床病理特征和无病生存的关系。使用基因本体论（GO）分析主要涉及 的生物学过程，STRING 在线构建其蛋白质相互作用网络，并筛选关键基因（枢纽基因）。
TCGA 显示 1018 例 NSCLC 组织中的 mRNA 高于 111 例相邻组织（ < 0.05）。在数据集“GSE157692”中，顺铂耐药细胞系中的 mRNA 更高（ = 3.80e-05）。 和 HRR 方向的枢纽基因是 和 。免疫组织化学显示，58 例 NSCLC 组织中的 FIGNL1 蛋白高于 58 例相邻组织（ < 0.01）。FIGNL1 与 NSCLC 中的性别、组织病理学类型和神经浸润有关。FIGNL1 高表达的 NSCLC 患者无病生存时间较短（ = 0.032）。
FIGNL1 与 NSCLC 的不良预后相关，可能涉及顺铂耐药。这些观察结果为探索 FIGNL1 作为 NSCLC 顺铂耐药的潜在生物标志物提供了临床依据。
